Telsey Advisory Group Has Lowered Expectations for Bath & Body Works (NYSE:BBWI) Stock Price

Bath & Body Works (NYSE:BBWIGet Free Report) had its target price reduced by equities researchers at Telsey Advisory Group from $25.00 to $22.00 in a research report issued on Thursday. The firm presently has a “market perform” rating on the stock. Telsey Advisory Group’s target price indicates a potential upside of 12.45% from the stock’s previous close.

Several other analysts also recently weighed in on BBWI. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Bath & Body Works from $21.00 to $22.00 and gave the stock a “hold” rating in a research report on Tuesday, March 3rd. Citigroup downgraded shares of Bath & Body Works from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $21.00 to $25.00 in a research report on Tuesday, February 17th. The Goldman Sachs Group reduced their price objective on shares of Bath & Body Works from $26.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. Raymond James Financial restated a “market perform” rating on shares of Bath & Body Works in a research report on Wednesday. Finally, Piper Sandler assumed coverage on shares of Bath & Body Works in a research report on Friday, May 15th. They set a “neutral” rating and a $20.00 price objective for the company. Three analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to MarketBeat.com, Bath & Body Works presently has an average rating of “Hold” and an average price target of $21.57.

Read Our Latest Report on Bath & Body Works

Bath & Body Works Price Performance

Bath & Body Works stock opened at $19.56 on Thursday. Bath & Body Works has a 1-year low of $14.27 and a 1-year high of $33.96. The stock has a market cap of $3.94 billion, a PE ratio of 6.21, a P/E/G ratio of 1.76 and a beta of 1.43. The stock’s fifty day moving average is $18.65 and its two-hundred day moving average is $20.24.

Bath & Body Works (NYSE:BBWIGet Free Report) last posted its quarterly earnings results on Wednesday, May 27th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.03. Bath & Body Works had a negative return on equity of 45.60% and a net margin of 8.90%.The company had revenue of $1.38 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same period last year, the firm earned $0.49 earnings per share. Bath & Body Works’s quarterly revenue was down 3.2% on a year-over-year basis. Bath & Body Works has set its Q2 2026 guidance at 0.300-0.300 EPS and its FY 2026 guidance at 2.400-2.650 EPS. On average, research analysts expect that Bath & Body Works will post 2.61 earnings per share for the current fiscal year.

Institutional Trading of Bath & Body Works

Several institutional investors and hedge funds have recently bought and sold shares of BBWI. Royal Bank of Canada raised its position in Bath & Body Works by 92.8% in the 1st quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock valued at $1,815,000 after purchasing an additional 28,815 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Bath & Body Works by 15.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock worth $19,586,000 after buying an additional 87,529 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Bath & Body Works by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock worth $17,063,000 after buying an additional 36,684 shares during the last quarter. Intech Investment Management LLC purchased a new position in Bath & Body Works during the 1st quarter worth $1,155,000. Finally, Geneos Wealth Management Inc. raised its position in Bath & Body Works by 217.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after buying an additional 801 shares during the last quarter. Hedge funds and other institutional investors own 95.14% of the company’s stock.

Trending Headlines about Bath & Body Works

Here are the key news stories impacting Bath & Body Works this week:

About Bath & Body Works

(Get Free Report)

Bath & Body Works, Inc is a leading specialty retailer focused on personal care, home fragrance and complementary products. Through its flagship Bath & Body Works brand, the company offers a diverse assortment of shower gels, lotions, fragrance mists, candles and home fragrance items. Its product portfolio also includes the White Barn Candle Co range of premium scented candles and diffusers. Bath & Body Works serves consumers through a combination of brick-and-mortar stores and e-commerce platforms, delivering seasonal collections, limited-edition releases and signature scent lines.

Founded in 1990 as part of Limited Brands (now L Brands), Bath & Body Works opened its first store in New Albany, Ohio, and quickly expanded across the United States.

Further Reading

Analyst Recommendations for Bath & Body Works (NYSE:BBWI)

Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.